Cancer prevention with rapamycin
Metrics: PDF 968 views | Full Text 5327 views | ?
Mikhail V. Blagosklonny1
1 Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
|Mikhail V. Blagosklonny,||email:||[email protected],
Keywords: chemoprevention; lung; rapamycin; aging; cancer
Received: February 27, 2023 Accepted: April 06, 2023 Published: April 14, 2023
Rapamycin (sirolimus) and other rapalogs (everolimus) are anti-cancer and anti-aging drugs, which delay cancer by directly targeting pre-cancerous cells and, indirectly, by slowing down organism aging. Cancer is an age-related disease and, figuratively, by slowing down time (and aging), rapamycin may delay cancer. In several dozen murine models, rapamycin robustly and reproducibly prevents cancer. Rapamycin slows cell proliferation and tumor progression, thus delaying the onset of cancer in carcinogen-treated, genetically cancer-prone and normal mice. Data on the use of rapamycin and everolimus in organ-transplant patients are consistent with their cancer-preventive effects. Treatment with rapamycin was proposed to prevent lung cancer in smokers and former smokers. Clinical trials in high-risk populations are warranted.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.